Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and
acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian
cancer